{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Brain PET in the Diagnosis of Alzheimer's Disease
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Description
The characteristic patterns of glucose metabolism on brain FDG-PET can help in differentiating Alzheimer's disease from other causes of dementia such as frontotemporal dementia and dementia of Lewy body. Amyloid brain PET may exclude significant amyloid deposition and thus Alzheimer's disease in the appropriate clinical setting. Method of Participation in the Learning Process/Evaluation Method Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form. Getting the Most out of the Activity As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed. While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.Purpose of Activity
To review the current role of brain PET imaging in the diagnosis of Alzheimer's dementia.Learning Objectives
After completing this continuing education activity you will be able to:
- Identify patterns of FDG spatial distribution in brain PET of patients with MCI, AD, frontotemporal dementia, and dementia of Lewy Body.
- Identify the value and discuss the appropriateness criteria for amyloid brain PET.
Disclosures
Dr Subramaniam was a speaker for Eli Lilly in 2013 in brain amyloid PET and received speaker fees. All staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no other financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity. Lippincott CME Institute has identified and resolved all conflicts of interest concerning this educational activity.
Price:
FREE
Credits:
- ACCME 2.0 CME
- ABNM 2.0 CME
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Qualified by the American Board of Nuclear Medicine (ABNM) in meeting the criteria for self-assessment toward the purpose of fulfilling requirements in the ABR Maintenance of Certification (MOC) Program.
Qualified by the American Board of Nuclear Medicine (ABNM) in meeting the criteria for self-assessment toward the purpose of fulfilling requirements in the ABR Maintenance of Certification (MOC) Program.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Professions:
Physician
Test Code: CNM1014
Published: Oct 2014
Expires: 1/1/2026
Sources:
Clinical Nuclear Medicine
Required Passing Score: 8/11 (72%)
Categories:
Diagnostic Studies
Specialties:
Nuclear Medicine